IL13RA2 and glioblastoma: Currently, clinical trials are on-going to evaluate the therapeutic efficacy of EGFRvIII-CAR (NCT03726515) and IL13Rα2-CAR (NCT04003649) T-cell therapy in combination with ICIs such as pembrolizumab or nivolumab in recurrent or refractory GBM patients (Table 1).